CD79B and acute myeloid leukemia: Transcriptomic analyses linked higher CD79B expression to immune response and T-cell activation pathways and to global patterns of immune-cell infiltration.<h4>Conclusion</h4>These exploratory data suggest that CD79B downregulation is a recurrent feature of MDS and AML and that CD79B may influence leukemic cell behavior and immune microenvironmental signals.